The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

FNZ employee shareholders told success more likely
Finance

FNZ employee shareholders told success more likely

Account show loss at global fintech widens. 

Victoria Young 05 Jun 2025
NZ Super ahead of the curve on US equities
Finance

NZ Super ahead of the curve on US equities

New Zealand’s sovereign wealth fund has been overweight in European equities.

Gregor Thompson 03 Jun 2025
Former Telecom chair Wayne Boyd honoured
Finance

Former Telecom chair Wayne Boyd honoured

Honours recognition for a lifetime of low-key, high-quality leadership.

Pattrick Smellie 02 Jun 2025
Andrew Barclay to leave Goldman Sachs NZ
Finance

Andrew Barclay to leave Goldman Sachs NZ

Andrew Barclay has been one of NZ’s most respected deal-makers.

Pattrick Smellie 20 May 2025